The Asia Pacific Blood Plasma Derivatives Market would witness market growth of 9.7% CAGR during the forecast period (2022-2028).
More than 100 distinct proteins are present in plasma, including albumin, immunoglobulins, fibrinogen, protease inhibitors, and coagulation factors. Plasma serves a crucial function in controlling blood pressure and transferring essential minerals, such as salt and potassium, to maintain the body's normal pH balance. It is produced by removing suspended cells and proteins. Plasma derivatives include unique plasma protein concentrates derived from blood plasma. These are obtained by the fractionation process.
Albumin, factor VIII and factor IX, immunoglobulins, and anti-inhibitor coagulation complex (AICC), including alpha 1-proteinase inhibitor concentrate, Rh immune globulin, and anti-thrombin III concentrate are plasma derivatives. Albumin is the most abundant and essential component of plasma protein, which is responsible for regulating the oncotic pressure in blood arteries and performing multiple transport tasks. Immunoglobulins are essential for eliciting an effective immune response to a pathogen or infectious illness. Factors VIII and IX are blood clotting factors that contribute to blood coagulation.
Immunoglobulin is primarily responsible for maintaining the osmotic pressure within blood vessels. Immunoglobulin is accountable for the development of immunity in response to the introduction of any foreign particle into the body. The increase in the frequency of life-threatening conditions, such as immunodeficiency, the increase in the geriatric population, and the increase in the use of blood plasma derivatives products are anticipated to drive the blood plasma market.
The expansion of the regional market is attributed to initiatives and authorizations by the governments throughout the region in order to export items, such as bovine protein and serum. According to the World Health Organization's 2011 Census, India is home to 104 million senior citizens or 8.6% of the total population. Women outnumber men among people aged 60 and older. Moreover, life expectancy is rising dramatically, resulting in a rise in the elderly population in the region. This rise in the geriatric population within the region is rapidly augmenting the growth of the regional blood plasma derivatives market.
The China market dominated the Asia Pacific Blood Plasma Derivatives Market by Country in 2021; thereby, achieving a market value of $5,665.4 Million by 2028. The Japan market is poised to grow at a CAGR of 9% during (2022 - 2028). Additionally, The India market would obtain a CAGR of 10.4% during (2022 - 2028).
Based on Application, the market is segmented into Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia, Von Willebrand's Disease, and Others. Based on End User, the market is segmented into Hospitals, Clinics, and Others. Based on Type, the market is segmented into Immunoglobulin, Albumin, Factor VIII, Factor IX, Hyperimmune Globulin, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Blood Plasma Derivatives Market is Projected to reach USD 72.5 Billion by 2028, at a CAGR of 9.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Biotest AG, LFB S.A., CSL Limited, Octapharma AG, Kedrion S.p.A, Sanofi S.A. and Fusion Health Care Pvt. Ltd.
By Application
By End User
By Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
